Clinical Trial Finder

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria (Healthy Patients):

• - Males and females, ages 18 to 55 years, inclusive, at screening - Healthy subjects, as determined by no clinically significant deviations from normal in medical history, physical examination, 12-lead ECGs, vital signs, and clinical laboratory results - Body mass index (BMI) of 18.0 to 30.0 kg/m2, inclusive, at screening - Body weight between 55 kg and 105 kg, inclusive, at screening - Women must not be breastfeeding Exclusion Criteria (Healthy Patients): - Previous participation in the current study - Participation in a drug study or exposure to any investigational drug or placebo within 2 months prior to (the first) drug administration in the current study - Employees of PRA or the Sponsor and their relatives - Any significant acute or chronic medical condition that presents a potential risk to the subject and/or that may compromise the objectives of the study, including active, or history of, liver disease, or intestinal disorder including irritable bowel syndrome - Current or recent (within 3 months of study treatment administration) gastrointestinal disease that could affect pharmacokinetics; history of cholecystectomy is not allowed Inclusion Criteria (Psoriasis Patients): - Males and females, ages 18 to 70 years, inclusive, at screening - BMI of 18.0 to 35.0 kg/m2, inclusive, at screening - Body weight between 55 kg and 120 kg, inclusive, at screening - Diagnosed with stable chronic plaque psoriasis, for at least 6 months prior to screening and be candidates for either photo-therapy or systemic treatment - Moderate-to-severe intensity of psoriasis as defined by: 1.

Affected body surface area (BSA) of ≥10% 2. Psoriasis Area and Severity Index (PASI) ≥12 3. Physician Global Assessment (PGA; 6-point scale) ≥3 Exclusion Criteria (Psoriasis Patients): - Previous participation in the current study - Participation in a drug study or exposure to any investigational drug or placebo within 2 months prior to (the first) drug administration in the current study - Employees of PRA or the Sponsor and their relatives - Any significant acute or chronic medical condition that presents a potential risk to the subject and/or that may compromise the objectives of the study, including active, or history of, liver disease, or intestinal disorder including irritable bowel syndrome - Current or recent (within 3 months of study treatment administration) gastrointestinal disease that could affect pharmacokinetics; history of cholecystectomy is not allowed Other protocol defined inclusion/exclusion criteria could apply